The United Kingdom and the United States have hammered out a significant trade agreement that will keep no import taxes on British drug exports being sold in the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has agreed to boost spending on drugs through the NHS. This move secures that tariffs on these key products will be held at nothing for a timeframe of 36 months.
This deal comes after recent threats to significantly raise tariffs on branded drug imports, with potential rates floated up to one hundred percent.
"This deal between the United Kingdom reinforces the worldwide climate for cutting-edge drugs and establishes long-overdue fairness to American-British drug exports," a release said.
Commercial Impact
Pharmaceuticals constitute one of the the United Kingdom's biggest goods shipped to the US, which is easily the biggest destination for large British pharmaceutical firms.
Trade data show that in the year prior to the third quarter, the UK shipped medicines totaling billions to the US. This amount made up 17.4% of British export trade in that period.
"This guarantee protects work, increases funding and sets the stage for the UK to emerge as a international leader for biotech and pharma," a government official stated.
Detailed NHS Changes
The agreement involves several notable commitments from the British government:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a goal to increase total public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The amount drug companies must pay back to the NHS to control costs will be restricted at fifteen percent. Last year, repayments topped 20%.
Broader Context
This agreement comes amid a long-running dispute between the drug companies and the British authorities over drug pricing and NHS adoption.
The disagreement were intensified by claims that American patients were paying significantly more for the identical medicines than consumers in the other developed nations.
Over the last 18 months, several large manufacturing plans in the UK have been paused or scrapped, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
One official acknowledged that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had decreased as a percentage of its overall budget over the last ten years.
